Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
Cancer, 06/23/09
Kantarjian H et al. - In a trial to assess the use of dasatinib and high-dose imatinib in chronic-phase chronic myeloid leukemia (CP-CML) resistant to imatinib, it was reported that after 2 yrs of follow-up, dasatinib demonstrated durable responses and improved response and progression-free survival (PFS) rates relative to high-dose imatinib.
Methods- A phase 2, open-label study was initiated of 150 pts with imatinib-resistant CP-CML who were randomized (2:1) to receive either dasatinib 70 mg twice daily (n=101) or high-dose imatinib 800 mg (400 mg twice daily; n=49).
- At a minimum follow-up of 2 yrs, dasatinib demonstrated higher rates of complete hematologic response (93% vs 82%), major cytogenetic response (MCyR) (53% vs 33%), and complete cytogenetic response (44% vs 18%).
- At 18 mos, MCyR was maintained in 90% of pts on the dasatinib arm and in 74% of pts on the high-dose imatinib arm.
- Major molecular response rates were more frequent with dasatinib than with high-dose imatinib (29% vs 12%).
- Estimated PFS also favored dasatinib.
Related Articles
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 92%
Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Blood, 10/02/09
Relevance Score: 87%
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/01/09
Relevance Score: 85%
Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder
The American Journal of the Medical Sciences, 11/13/09
Relevance Score: 83%
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
Cancer Science, 10/08/09
Relevance Score: 80%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, 12/04/09
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Three-dimensional (3D) Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to MEK Inhibitors
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Two antimalaria drugs are tolerated regimens in regions with resistance
Formulary , 12/02/09
Imipenem Resistance in Pseudomonas aeruginosa: Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes
Infection Control and Hospital Epidemiology, 12/02/09
Sponsor
Article Search
Sponsor